Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Listed
Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2026-06-16 AGM Information
Country CN China
Listing Shanghai Stock Exchange 603566 · 1 venue

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯2026年第二次临时股东会会议资料
AGM Information Classification · 100% confidence The document is titled as meeting materials for the "2026 Second Extraordinary General Meeting of Shareholders" of the company, including meeting organization rules, voting procedures, meeting agenda, and detailed proposals for shareholder approval. It does not contain any financial statements, management discussions, or audit opinions. Rather, it is material prepared for the shareholders meeting. The content primarily supports the execution of the extraordinary shareholders meeting and facilitates informed voting decisions. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting.
2026-06-16 Chinese
普莱柯董事会秘书工作规则（2026年6月修订）
Governance Information Classification · 95% confidence The document is titled '董事会秘书工作规则' which translates to 'Board Secretary Work Rules'. It outlines the qualifications, duties, appointment, and responsibilities of the board secretary at a company, referencing laws and internal rules. The content deals with governance processes rather than financial results, report announcements, or shareholder meetings. It does not contain financial data, earnings information, regulatory filings about share dealings, nor is it a presentation or call transcript. It is a governance-related internal rules document about board/management roles and procedures, fitting the definition of Governance Information (CGR). The document length is 4204 characters, relatively concise but sufficiently detailed to represent the rules themselves rather than an announcement about them.
2026-06-14 Chinese
普莱柯关于召开2026年第二次临时股东会的通知
AGM Information Classification · 95% confidence The document is a notice regarding the convening of the 2026 second extraordinary shareholders meeting (临时股东会) of Pulike Bioengineering Co., Ltd. It details the meeting date, location, voting methods (on-site and online), agenda items to be voted upon, shareholder attendance, registration details, and includes an authorization proxy form for voting. It is an announcement of an upcoming shareholder meeting, not the meeting materials, presentations, voting results, or the actual resolutions passed. This fits the category of providing information and notice about a general meeting rather than the details shared during an AGM or the voting results. Therefore, the document should be classified as "Notice for a Shareholders Meeting" which corresponds to AGM Information (AGM-R). Its length (3363 characters) and content correspond to a meeting notification rather than a full annual report, voting result, or legal filing. Hence, the most appropriate classification is AGM Information (AGM-R) with high confidence.
2026-06-14 Chinese
华泰联合证券有限责任公司关于普莱柯生物工程股份有限公司终止部分募集资金投资项目的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsor institution concerning the termination of a specific investment project funded by a company's raised capital (募集资金). The content extensively discusses the use of funds raised via non-public stock issuance, project progress, termination decisions, regulatory and shareholder approval steps, and the sponsor's audit and opinion on the matter. It references compliance with securities regulations and discloses financial figures related to raised funds and their use. This kind of document is typically a specialized regulatory filing reporting an important capital use update rather than a full financial report, annual report, or earnings release. It does not contain full financial statements or earnings data itself—merely an official announcement and regulatory opinion on the change in use of fundraising capital. The sponsor firm's detailed opinion and regulatory references indicate this is a Regulatory Filing (RNS) describing the review and confirmation of a material capital project change.
2026-06-14 Chinese
普莱柯第六届董事会第三次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a Board of Directors meeting, including mention of meeting attendance, voting results, and summaries of agenda items. It details board approvals on various governance topics such as remuneration system revisions and the scheduling of a shareholder meeting. This content aligns with announcements about board or senior management decisions and changes rather than full reports, presentations, or financial disclosures. The length is 1272 characters, much shorter than full reports. Therefore, the document fits best in the category describing Board/Management Information announcements (Code: MANG).
2026-06-14 Chinese
普莱柯关于终止部分募集资金投资项目的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about the termination of part of a fundraising investment project by the company. It involves specifics about the non-public issuance of shares, the allocation and usage of raised funds, the project's status, reasons for termination, and procedural approvals including board and shareholder meetings. There are no comprehensive financial statements or performance results presented; instead, the focus is on the status of capital raised and its planned usage changes. The document is not a report like an Annual Report or Interim Report but rather an update on capital usage related to fundraising. This fits the definition of a Capital/Financing Update (CAP). The length is about 3833 characters, which is insufficient for a full financial report but suitable for a detailed announcement of financing activities.
2026-06-14 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.